Mativ Business Model Canvas
Unlock the strategic Business Model Canvas: blueprint to value creation and scaling
Unlock the full strategic blueprint behind Mativ’s business model with our complete Business Model Canvas—three concise sections reveal how Mativ creates value, scales operations, and captures market share. Ideal for investors, consultants, and founders seeking actionable insights; download the editable Word and Excel files to benchmark and adapt proven strategies today.
Partnerships
Advanced raw material suppliers
Strategic relationships with polymer, fiber, pulp and specialty chemical suppliers secure critical inputs for filtration, liners and healthcare media, supporting Mativ's 2024 product continuity targets. Multi-sourcing and qualification programs reduce supply risk and stabilize pricing across global sites. Joint development with suppliers enables tailored material properties for proprietary media. Sustainability-aligned partners advance recycled, bio-based and low-emission inputs in 2024 procurement.
Equipment & process OEMs
Partnerships with coating, extrusion, meltblown, and calendaring OEMs drive measurable precision, yield, and throughput gains through co-engineering that creates unique process windows for high-performance materials. Access to OEM pilot lines accelerates scale-up and customer sampling while long-term service and spare-part agreements reduce downtime and preserve OEE. These partnerships support faster commercialization and predictable capacity expansion.
Converters, laminators & label ecosystem
Alliances with downstream converters and label producers ensure end-use performance in release liners and packaging, supporting validation across adhesion, release force and printability through joint trials. These collaborations expanded Mativ’s reach into new markets and SKUs, contributing to growth as the global release liner market reached about $6.2 billion in 2024. Feedback loops from converters drive product refinements and launch of targeted SKUs, shortening development cycles and reducing field defects.
Healthcare & regulatory partners
Clinical advisors, notified bodies, and accredited testing labs ensure Mativ healthcare materials meet ISO 13485 and FDA 510(k)/PMA expectations, streamlining regional certifications and EU MDR compliance that remained a primary regulatory focus in 2024. Post-market surveillance programs and routine quality audits reinforce trust and traceability. Shared risk frameworks with partners accelerate time-to-market for new medical substrates.
- Clinical advisors: protocol design and adverse event review
- Notified bodies/testing labs: conformity assessment and bench/biocompatibility testing
- Certifications: ISO 13485, FDA 510(k)/PMA, EU MDR alignment
- Post-market: surveillance, audits, shared risk agreements
Logistics & sustainability bodies
Global logistics partners provide temperature- and humidity-controlled transport critical for perishables; the cold chain market reached about $242B in 2024. FSC/PEFC and ISO certifications plus eco-labels validate claims, while carbon accounting collaborations increase Scope 3 transparency (Scope 3 often ~75% of corporate emissions). Regional DC partners cut lead times up to 30% and freight costs 15–25%.
- Cold chain market: $242B (2024)
- Scope 3 share: ~75%
- Lead time reduction: up to 30%
- Freight cost savings: 15–25%
Alliances secure supply, accelerate regulatory clearance and cut lead times up to 30%
Strategic supplier and OEM alliances secure inputs and scale-up, de-risking supply and supporting 2024 continuity targets. Converter and clinical partner networks accelerate commercialization and regulatory clearance (ISO 13485, FDA 510(k)/PMA, EU MDR). Logistics and sustainability partners cut lead times and emissions while enabling market expansion.
| Metric | Value (2024) |
|---|---|
| Release liner market | $6.2B |
| Cold chain market | $242B |
| Scope 3 share | ~75% |
| Lead time reduction | up to 30% |
| Freight cost savings | 15–25% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written business model tailored to Mativ’s strategy, organized into nine BMC blocks with full narratives covering value propositions, customer segments, channels, revenue streams, key activities, partners, resources, and cost structure; includes SWOT-linked competitive analysis and polished design for investor presentations, bank funding, and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Mativ’s business model with editable cells, relieving the pain of fragmented strategy documents and saving time on formatting and alignment. Perfect for fast internal alignment, board-ready summaries, and collaborative iteration.
Activities
Material science R&D
Formulation of fibers, polymers and coatings focuses on meeting filtration efficiency targets such as N95-level 95% capture at 0.3 µm, release performance and healthcare standards. Lab testing spans mechanical (tensile, burst), chemical (compatibility, extractables) and thermal metrics to validate safety. Rapid prototyping and pilot runs enable customer trials and scale-up. IP generation secures novel constructions and processes.
Custom application engineering
Custom application engineering partners with OEMs to design substrates meeting target porosity, basis weight, caliper, and surface energy, using simulation and DOE to accelerate scale-up; on-site trials and line-integration support ensure production readiness. Documentation aligns with technical and regulatory specs such as ISO 13485 and FDA 21 CFR Part 820 (as of 2024).
Advanced manufacturing & QA
Advanced manufacturing & QA integrate precision coating, extrusion, meltblown and calendaring at scale with inline inspection and SPC ensuring tight tolerances. Lot-level traceability and CoA issuance enable product release and regulatory compliance. Continuous improvement programs focus on yield enhancement and scrap reduction through root-cause analysis and process control.
Global sourcing & supply chain
Global sourcing centers on strategic procurement of pulp, resins, and additives with hedging programs and dual-sourcing for critical inputs to limit price and supply shocks; inventory planning and VMI target defined service levels while complying with trade, customs, and sustainability standards (including Scope 3 supplier requirements in 2024).
- Strategic procurement & hedging
- Inventory planning & VMI
- Dual-sourcing & risk mitigation
- Trade, customs & sustainability compliance
Regulatory, EHS & sustainability
- Regulatory: ISO, FDA, REACH maintained
- EHS: plant-wide safety & environmental programs
- Sustainability: LCA-backed claims (2024)
- Customer: audit-ready documentation
95% N95 capture at 0.3 µm - ISO13485 & FDA 21 CFR ready
Formulation targets N95-level 95% capture at 0.3 µm, release performance and healthcare compatibility. Lab testing covers mechanical, chemical and thermal validation; rapid prototyping and pilot runs enable scale-up. Compliance with ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001 and REACH guides documentation and QA. Global sourcing emphasizes dual-sourcing, hedging and VMI; 2024 LCA supports sustainability claims.
| Activity | Metric | 2024 |
|---|---|---|
| Filtration spec | N95 capture | 95% @0.3 µm |
| Standards | Certifications | ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001, REACH |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Mativ Business Model Canvas you'll receive after purchase; it's not a mockup or sample. This live preview reflects the same content, structure, and formatting included in the final file. Once purchased, you'll download the complete, editable document ready for presentation, editing, or sharing.
Unlock the strategic Business Model Canvas: blueprint to value creation and scaling
Unlock the full strategic blueprint behind Mativ’s business model with our complete Business Model Canvas—three concise sections reveal how Mativ creates value, scales operations, and captures market share. Ideal for investors, consultants, and founders seeking actionable insights; download the editable Word and Excel files to benchmark and adapt proven strategies today.
Partnerships
Advanced raw material suppliers
Strategic relationships with polymer, fiber, pulp and specialty chemical suppliers secure critical inputs for filtration, liners and healthcare media, supporting Mativ's 2024 product continuity targets. Multi-sourcing and qualification programs reduce supply risk and stabilize pricing across global sites. Joint development with suppliers enables tailored material properties for proprietary media. Sustainability-aligned partners advance recycled, bio-based and low-emission inputs in 2024 procurement.
Equipment & process OEMs
Partnerships with coating, extrusion, meltblown, and calendaring OEMs drive measurable precision, yield, and throughput gains through co-engineering that creates unique process windows for high-performance materials. Access to OEM pilot lines accelerates scale-up and customer sampling while long-term service and spare-part agreements reduce downtime and preserve OEE. These partnerships support faster commercialization and predictable capacity expansion.
Converters, laminators & label ecosystem
Alliances with downstream converters and label producers ensure end-use performance in release liners and packaging, supporting validation across adhesion, release force and printability through joint trials. These collaborations expanded Mativ’s reach into new markets and SKUs, contributing to growth as the global release liner market reached about $6.2 billion in 2024. Feedback loops from converters drive product refinements and launch of targeted SKUs, shortening development cycles and reducing field defects.
Healthcare & regulatory partners
Clinical advisors, notified bodies, and accredited testing labs ensure Mativ healthcare materials meet ISO 13485 and FDA 510(k)/PMA expectations, streamlining regional certifications and EU MDR compliance that remained a primary regulatory focus in 2024. Post-market surveillance programs and routine quality audits reinforce trust and traceability. Shared risk frameworks with partners accelerate time-to-market for new medical substrates.
- Clinical advisors: protocol design and adverse event review
- Notified bodies/testing labs: conformity assessment and bench/biocompatibility testing
- Certifications: ISO 13485, FDA 510(k)/PMA, EU MDR alignment
- Post-market: surveillance, audits, shared risk agreements
Logistics & sustainability bodies
Global logistics partners provide temperature- and humidity-controlled transport critical for perishables; the cold chain market reached about $242B in 2024. FSC/PEFC and ISO certifications plus eco-labels validate claims, while carbon accounting collaborations increase Scope 3 transparency (Scope 3 often ~75% of corporate emissions). Regional DC partners cut lead times up to 30% and freight costs 15–25%.
- Cold chain market: $242B (2024)
- Scope 3 share: ~75%
- Lead time reduction: up to 30%
- Freight cost savings: 15–25%
Alliances secure supply, accelerate regulatory clearance and cut lead times up to 30%
Strategic supplier and OEM alliances secure inputs and scale-up, de-risking supply and supporting 2024 continuity targets. Converter and clinical partner networks accelerate commercialization and regulatory clearance (ISO 13485, FDA 510(k)/PMA, EU MDR). Logistics and sustainability partners cut lead times and emissions while enabling market expansion.
| Metric | Value (2024) |
|---|---|
| Release liner market | $6.2B |
| Cold chain market | $242B |
| Scope 3 share | ~75% |
| Lead time reduction | up to 30% |
| Freight cost savings | 15–25% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written business model tailored to Mativ’s strategy, organized into nine BMC blocks with full narratives covering value propositions, customer segments, channels, revenue streams, key activities, partners, resources, and cost structure; includes SWOT-linked competitive analysis and polished design for investor presentations, bank funding, and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Mativ’s business model with editable cells, relieving the pain of fragmented strategy documents and saving time on formatting and alignment. Perfect for fast internal alignment, board-ready summaries, and collaborative iteration.
Activities
Material science R&D
Formulation of fibers, polymers and coatings focuses on meeting filtration efficiency targets such as N95-level 95% capture at 0.3 µm, release performance and healthcare standards. Lab testing spans mechanical (tensile, burst), chemical (compatibility, extractables) and thermal metrics to validate safety. Rapid prototyping and pilot runs enable customer trials and scale-up. IP generation secures novel constructions and processes.
Custom application engineering
Custom application engineering partners with OEMs to design substrates meeting target porosity, basis weight, caliper, and surface energy, using simulation and DOE to accelerate scale-up; on-site trials and line-integration support ensure production readiness. Documentation aligns with technical and regulatory specs such as ISO 13485 and FDA 21 CFR Part 820 (as of 2024).
Advanced manufacturing & QA
Advanced manufacturing & QA integrate precision coating, extrusion, meltblown and calendaring at scale with inline inspection and SPC ensuring tight tolerances. Lot-level traceability and CoA issuance enable product release and regulatory compliance. Continuous improvement programs focus on yield enhancement and scrap reduction through root-cause analysis and process control.
Global sourcing & supply chain
Global sourcing centers on strategic procurement of pulp, resins, and additives with hedging programs and dual-sourcing for critical inputs to limit price and supply shocks; inventory planning and VMI target defined service levels while complying with trade, customs, and sustainability standards (including Scope 3 supplier requirements in 2024).
- Strategic procurement & hedging
- Inventory planning & VMI
- Dual-sourcing & risk mitigation
- Trade, customs & sustainability compliance
Regulatory, EHS & sustainability
- Regulatory: ISO, FDA, REACH maintained
- EHS: plant-wide safety & environmental programs
- Sustainability: LCA-backed claims (2024)
- Customer: audit-ready documentation
95% N95 capture at 0.3 µm - ISO13485 & FDA 21 CFR ready
Formulation targets N95-level 95% capture at 0.3 µm, release performance and healthcare compatibility. Lab testing covers mechanical, chemical and thermal validation; rapid prototyping and pilot runs enable scale-up. Compliance with ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001 and REACH guides documentation and QA. Global sourcing emphasizes dual-sourcing, hedging and VMI; 2024 LCA supports sustainability claims.
| Activity | Metric | 2024 |
|---|---|---|
| Filtration spec | N95 capture | 95% @0.3 µm |
| Standards | Certifications | ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001, REACH |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Mativ Business Model Canvas you'll receive after purchase; it's not a mockup or sample. This live preview reflects the same content, structure, and formatting included in the final file. Once purchased, you'll download the complete, editable document ready for presentation, editing, or sharing.
Description
Unlock the strategic Business Model Canvas: blueprint to value creation and scaling
Unlock the full strategic blueprint behind Mativ’s business model with our complete Business Model Canvas—three concise sections reveal how Mativ creates value, scales operations, and captures market share. Ideal for investors, consultants, and founders seeking actionable insights; download the editable Word and Excel files to benchmark and adapt proven strategies today.
Partnerships
Advanced raw material suppliers
Strategic relationships with polymer, fiber, pulp and specialty chemical suppliers secure critical inputs for filtration, liners and healthcare media, supporting Mativ's 2024 product continuity targets. Multi-sourcing and qualification programs reduce supply risk and stabilize pricing across global sites. Joint development with suppliers enables tailored material properties for proprietary media. Sustainability-aligned partners advance recycled, bio-based and low-emission inputs in 2024 procurement.
Equipment & process OEMs
Partnerships with coating, extrusion, meltblown, and calendaring OEMs drive measurable precision, yield, and throughput gains through co-engineering that creates unique process windows for high-performance materials. Access to OEM pilot lines accelerates scale-up and customer sampling while long-term service and spare-part agreements reduce downtime and preserve OEE. These partnerships support faster commercialization and predictable capacity expansion.
Converters, laminators & label ecosystem
Alliances with downstream converters and label producers ensure end-use performance in release liners and packaging, supporting validation across adhesion, release force and printability through joint trials. These collaborations expanded Mativ’s reach into new markets and SKUs, contributing to growth as the global release liner market reached about $6.2 billion in 2024. Feedback loops from converters drive product refinements and launch of targeted SKUs, shortening development cycles and reducing field defects.
Healthcare & regulatory partners
Clinical advisors, notified bodies, and accredited testing labs ensure Mativ healthcare materials meet ISO 13485 and FDA 510(k)/PMA expectations, streamlining regional certifications and EU MDR compliance that remained a primary regulatory focus in 2024. Post-market surveillance programs and routine quality audits reinforce trust and traceability. Shared risk frameworks with partners accelerate time-to-market for new medical substrates.
- Clinical advisors: protocol design and adverse event review
- Notified bodies/testing labs: conformity assessment and bench/biocompatibility testing
- Certifications: ISO 13485, FDA 510(k)/PMA, EU MDR alignment
- Post-market: surveillance, audits, shared risk agreements
Logistics & sustainability bodies
Global logistics partners provide temperature- and humidity-controlled transport critical for perishables; the cold chain market reached about $242B in 2024. FSC/PEFC and ISO certifications plus eco-labels validate claims, while carbon accounting collaborations increase Scope 3 transparency (Scope 3 often ~75% of corporate emissions). Regional DC partners cut lead times up to 30% and freight costs 15–25%.
- Cold chain market: $242B (2024)
- Scope 3 share: ~75%
- Lead time reduction: up to 30%
- Freight cost savings: 15–25%
Alliances secure supply, accelerate regulatory clearance and cut lead times up to 30%
Strategic supplier and OEM alliances secure inputs and scale-up, de-risking supply and supporting 2024 continuity targets. Converter and clinical partner networks accelerate commercialization and regulatory clearance (ISO 13485, FDA 510(k)/PMA, EU MDR). Logistics and sustainability partners cut lead times and emissions while enabling market expansion.
| Metric | Value (2024) |
|---|---|
| Release liner market | $6.2B |
| Cold chain market | $242B |
| Scope 3 share | ~75% |
| Lead time reduction | up to 30% |
| Freight cost savings | 15–25% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written business model tailored to Mativ’s strategy, organized into nine BMC blocks with full narratives covering value propositions, customer segments, channels, revenue streams, key activities, partners, resources, and cost structure; includes SWOT-linked competitive analysis and polished design for investor presentations, bank funding, and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Mativ’s business model with editable cells, relieving the pain of fragmented strategy documents and saving time on formatting and alignment. Perfect for fast internal alignment, board-ready summaries, and collaborative iteration.
Activities
Material science R&D
Formulation of fibers, polymers and coatings focuses on meeting filtration efficiency targets such as N95-level 95% capture at 0.3 µm, release performance and healthcare standards. Lab testing spans mechanical (tensile, burst), chemical (compatibility, extractables) and thermal metrics to validate safety. Rapid prototyping and pilot runs enable customer trials and scale-up. IP generation secures novel constructions and processes.
Custom application engineering
Custom application engineering partners with OEMs to design substrates meeting target porosity, basis weight, caliper, and surface energy, using simulation and DOE to accelerate scale-up; on-site trials and line-integration support ensure production readiness. Documentation aligns with technical and regulatory specs such as ISO 13485 and FDA 21 CFR Part 820 (as of 2024).
Advanced manufacturing & QA
Advanced manufacturing & QA integrate precision coating, extrusion, meltblown and calendaring at scale with inline inspection and SPC ensuring tight tolerances. Lot-level traceability and CoA issuance enable product release and regulatory compliance. Continuous improvement programs focus on yield enhancement and scrap reduction through root-cause analysis and process control.
Global sourcing & supply chain
Global sourcing centers on strategic procurement of pulp, resins, and additives with hedging programs and dual-sourcing for critical inputs to limit price and supply shocks; inventory planning and VMI target defined service levels while complying with trade, customs, and sustainability standards (including Scope 3 supplier requirements in 2024).
- Strategic procurement & hedging
- Inventory planning & VMI
- Dual-sourcing & risk mitigation
- Trade, customs & sustainability compliance
Regulatory, EHS & sustainability
- Regulatory: ISO, FDA, REACH maintained
- EHS: plant-wide safety & environmental programs
- Sustainability: LCA-backed claims (2024)
- Customer: audit-ready documentation
95% N95 capture at 0.3 µm - ISO13485 & FDA 21 CFR ready
Formulation targets N95-level 95% capture at 0.3 µm, release performance and healthcare compatibility. Lab testing covers mechanical, chemical and thermal validation; rapid prototyping and pilot runs enable scale-up. Compliance with ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001 and REACH guides documentation and QA. Global sourcing emphasizes dual-sourcing, hedging and VMI; 2024 LCA supports sustainability claims.
| Activity | Metric | 2024 |
|---|---|---|
| Filtration spec | N95 capture | 95% @0.3 µm |
| Standards | Certifications | ISO 13485, FDA 21 CFR Part 820, ISO 9001/14001, REACH |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Mativ Business Model Canvas you'll receive after purchase; it's not a mockup or sample. This live preview reflects the same content, structure, and formatting included in the final file. Once purchased, you'll download the complete, editable document ready for presentation, editing, or sharing.
